Categories: Wire Stories

First Experiments in Space for COVID-19 Drug Research With Kirara

TOKYO–(BUSINESS WIRE)–In June 2020, a consortium has been initiated by InnoStudio Inc. (HU) for the development and validation of highly efficient active compounds against SARS-CoV-2 while conducting drug discovery simultaneously and in a synchronized manner in space and on Earth.

InnoStudio will launch their samples of remdesivir-SBECD to the International Space Station (ISS), using the commercial service “Kirara” provided by Japan Manned Space Systems Corporation (JAMSS), which is to be launched in December 2020 (Kirara#2). This is the first space experiment for COVID-19 drug discovery research in the world*.

*by investigation of JAMSS and InnoStudio

Remdesivir, to be applicable for its intravenous infusion, requires formulation by the excipient cyclodextrin called SBECD. Although it is considered today as one of the most promising drugs for COVID-19 treatment, remarkable efficacy of remdesivir-SBECD complex has not yet been confirmed. This mission aims to deepen our understanding of the mechanism of remdesivir-SBECD formulation by studying the effect of microgravity on the complex formation properties of remdesivir and SBECD.

About Kirara

Kirara is a high-quality protein crystal growth service provided by JAMSS for drug discovery support. This technology was realized through a technical tie-up with Confocal Science, which has been supporting protein crystal generation on ground and in space since its foundation in 1994. The small incubator, which JAMSS developed and in which crystals are grown, is launched through the ICE Cubes Service and accommodated in the ICE Cubes Facility (ICF) owned by Space Applications Services who has a commercial partnership with the European Space Agency (ESA). Kirara is a commercial service partnership between Japanese and European companies. It could be applied to the field of materials such as cellulose as well as drug discovery support.

Kirara service URL: https://www.jamss.co.jp/en/kirara/index.html

About JAMSS

Japan Manned Space Systems Corporation (JAMSS), founded in 1990, is working for the operations and utilization of the Japanese Experiment Module �Kibo” at the International Space Station and has gained extensive manned space technology experience as a leading company of human space flight in Japan.

Related Articles

JAMSS supports COVID-19 space research consortium

https://www.jamss.co.jp/en/kirara/news/index.html?idx=T1592282381

FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH

https://cyclodextrinnews.com/2020/11/11/first-experiments-in-space-for-covid-19-drug-research

Contacts

Toshiyuki Tosa

+81-3-3211-2002

jamss-koho@jamss.co.jp

Alex

Recent Posts

Fabrinet Announces Third Quarter Fiscal Year 2024 Financial Results

Exceeds Guidance Ranges with Record Revenue and Net Income Per Share BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN),…

5 hours ago

South Korea Data Center Market Investment Analysis Report 2024-2029: Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "South Korea Data Center Market - Investment Analysis & Growth Opportunities 2024-2029" report…

8 hours ago

Revitalized “Marco Polo” Opera Celebrates Sino-Italian Ties at Guangzhou Opera House

GUANGZHOU, China--(BUSINESS WIRE)--On May 3rd and 4th, the Guangzhou Opera House welcomed nearly 200 international…

9 hours ago

BrainChip Earns Australian Patent for Improved Spiking Neural Network

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…

9 hours ago

NetApp Appoints Market Growth and Revenue Operations Leader, Dallas Olson to Chief Commercial Officer Role

SAN JOSE, Calif.--(BUSINESS WIRE)--NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced Dallas Olson…

10 hours ago

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on…

11 hours ago